Nova Eye Medical has reported a record US$6.1 million in sales for the December 2025 quarter, driven by strong US demand and a 24% annual growth rate that outpaces the industry.
- Record US$6.1 million sales in December 2025 quarter, up 38% year-on-year
- Six-month sales reached US$10.9 million, a 29% increase on prior period
- Last twelve months sales of ~US$21 million, growing 24% and tripling industry growth
- US market sales grew at a 40% compounded annual growth rate over six halves
- China market approved for iTrack™ Advance, sales expected to start in 2026
Record Sales Momentum
Nova Eye Medical Limited (ASX – EYE) has delivered a standout performance for the December 2025 quarter, posting record global sales of US$6.1 million. This represents a 38% increase compared to the same quarter last year and a 25% rise from the previous quarter, underscoring the company’s accelerating market traction.
The six months ended December 2025 saw sales climb to US$10.9 million, up 29% year-on-year, while the last twelve months recorded revenue of approximately US$21 million. This 24% growth rate notably outpaces the broader glaucoma surgical devices industry, which Marketscope estimates is growing at around 8% annually.
US Market Drives Growth
The United States remains the powerhouse behind Nova Eye Medical’s expansion, with six consecutive halves of sales growth culminating in a compound annual growth rate (CAGR) of roughly 40%. The company’s flagship product, iTrack™ Advance, a minimally invasive glaucoma surgical device, has now been used in about 180,000 procedures worldwide. Its growing adoption reflects increasing surgeon confidence in its ability to restore natural eye fluid outflow and reduce reliance on medications.
While the US market leads, other regions show mixed results. Sales in Germany were relatively flat, while the Rest of World (ROW) segment more than doubled, albeit from a smaller base. China presents a promising frontier following regulatory approval of iTrack™ Advance in September 2025, with sales expected to commence in 2026, potentially unlocking significant new revenue streams.
Strategic Outlook and Market Position
Nova Eye Medical’s performance highlights its successful commercial strategy and the increasing global acceptance of its ophthalmic technologies. The company’s dual manufacturing footprint in California and New Zealand supports its global distribution network, positioning it well to capitalize on expanding demand for innovative glaucoma treatments.
Despite the strong growth, the company’s sales figures remain unaudited, and currency fluctuations could impact reported revenue in Australian dollars. Nonetheless, the robust US growth and upcoming China market entry provide a compelling growth narrative for investors watching the medical devices sector.
Bottom Line?
With US sales momentum strong and China on the horizon, Nova Eye Medical’s next steps will be critical to sustaining its impressive growth trajectory.
Questions in the middle?
- How will Nova Eye Medical capitalise on the newly approved Chinese market in 2026?
- Can the company maintain its 40% US sales CAGR amid increasing competition?
- What impact will currency fluctuations have on reported Australian dollar revenues?